Cargando…

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas

BACKGROUND: DNA methylation of the immune checkpoint gene PD-L1 has recently been shown to be associated with PD-L1 mRNA expression in various malignancies. This study aimed to investigate the association of PD-L1 and PD-L2 methylation with mRNA expression, immune cell infitration, protein expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franzen, Alina, Vogt, Timo J., Müller, Tim, Dietrich, Jörn, Schröck, Andreas, Golletz, Carsten, Brossart, Peter, Bootz, Friedrich, Landsberg, Jennifer, Kristiansen, Glen, Dietrich, Dimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787495/ https://www.ncbi.nlm.nih.gov/pubmed/29416641 http://dx.doi.org/10.18632/oncotarget.23080

Ejemplares similares

PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients
por: Goltz, Diane, et al.
Publicado: (2017)

PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
por: Müller, Tim, et al.
Publicado: (2017)

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
por: Röver, Lea Kristin, et al.
Publicado: (2018)

Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome
por: Han, Rui, et al.
Publicado: (2021)

Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
por: Hoffmann, Friederike, et al.
Publicado: (2020)

Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients
por: de Vos, Luka, et al.
Publicado: (2017)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer
por: Zhou, Xuan, et al.
Publicado: (2022)

PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
por: Gevensleben, Heidrun, et al.
Publicado: (2016)

Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer
por: Elomaa, Hanna, et al.
Publicado: (2023)

PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2017)

CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients
por: Goltz, Diane, et al.
Publicado: (2016)

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
por: Straub, Melanie, et al.
Publicado: (2016)

Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma
por: Holderried, Tobias A. W., et al.
Publicado: (2019)

DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature
por: Sailer, Verena, et al.
Publicado: (2019)

Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020)

PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2016)

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
por: Zhang, Wenxin, et al.
Publicado: (2023)

Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2020)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2017)

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
por: Du, Ziming, et al.
Publicado: (2014)

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas
por: Sailer, Verena, et al.
Publicado: (2018)

Identification of PDCD1 and PDCD1LG2 as Prognostic Biomarkers and Associated with Immune Infiltration in Hepatocellular Carcinoma
por: Li, Wang, et al.
Publicado: (2022)

Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
por: Fabrizio, Federico Pio, et al.
Publicado: (2018)

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response
por: Kelly, Andrew D, et al.
Publicado: (2021)

Identification and characterization of novel CD274 (PD‐L1) regulating microRNAs and their functional relevance in melanoma
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer
por: Yang, Lin, et al.
Publicado: (2023)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai, Chun-Yi, et al.
Publicado: (2021)

Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD‐L1 (CD274)‐expression: Possible roles of tumour micro environmental factors for CD274 expression
por: Inaguma, Shingo, et al.
Publicado: (2017)

Nectin-4 is widely expressed in head and neck squamous cell carcinoma
por: Sanders, Christine, et al.
Publicado: (2022)

Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study
por: Bergheim, Julia, et al.
Publicado: (2018)

Relationship of tumor PD‐L1 (CD274) expression with lower mortality in lung high‐grade neuroendocrine tumor
por: Inamura, Kentaro, et al.
Publicado: (2017)

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
por: Guo, Lei, et al.
Publicado: (2016)

Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma
por: Ugai, Tomotaka, et al.
Publicado: (2021)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
por: Wu, Xuemei, et al.
Publicado: (2023)

Inverse relationship between Fusobacterium nucleatum amount and tumor CD274 (PD‐L1) expression in colorectal carcinoma
por: Ugai, Tomotaka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9qdd2i9cq1k3fa68ckdtn1f98h